| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SNRPD1 |
| Uniprot No | P62314 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-119aa |
| 氨基酸序列 | MKLVRFLMKL SHETVTIELK NGTQVHGTIT GVDVSMNTHL KAVKMTLKNR EPVQLETLSI RGNNIRYFIL PDSLPLDTLL VDVEPKVKSK KREAVAGRGR GRGRGRGRGR GRGRGGPRR |
| 预测分子量 | 13,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SNRPD1重组蛋白的3篇示例参考文献(注：内容为示例，建议通过学术数据库核实最新研究)：
---
1. **文献名称**: *"Recombinant SNRPD1 expression and its role in spliceosome assembly"*
**作者**: Smith A, et al.
**摘要**: 该研究成功在大肠杆菌中重组表达了人源SNRPD1蛋白，并优化了纯化条件。通过体外剪接体组装实验，证明重组SNRPD1对U1 snRNP复合物的形成至关重要，并解析了其与其他剪接因子(如SNRPB)的相互作用位点。
2. **文献名称**: *"Structural analysis of SNRPD1 in the Sm protein complex using cryo-EM"*
**作者**: Lee J, et al.
**摘要**: 利用冷冻电镜技术分析了重组SNRPD1与Sm蛋白复合物(包括SNRPD2、SNRPE等)的三维结构，揭示了SNRPD1在维持复合物稳定性及pre-mRNA结合中的关键结构域，为剪接机制提供新见解。
3. **文献名称**: *"SNRPD1 overexpression promotes cancer cell proliferation via mRNA splicing dysregulation"*
**作者**: Chen L, et al.
**摘要**: 通过重组SNRPD1在乳腺癌细胞中的过表达实验，发现其异常表达导致特定肿瘤相关基因(如MYC)的mRNA剪接异常，进而促进细胞周期进展，提示SNRPD1作为潜在癌症治疗靶点。
---
**说明**：以上文献为示例，实际研究可能需检索PubMed、Web of Science等平台，关键词“SNRPD1 recombinant”“SNRPD1 spliceosome”等可获取最新结果。
SNRPD1 (Small Nuclear Ribonucleoprotein D1 Polypeptide) is a core component of the spliceosome, a dynamic molecular machinery responsible for pre-mRNA splicing in eukaryotic cells. Encoded by the SNRPD1 gene, this protein belongs to the SM family of proteins, which are essential for assembling and stabilizing the spliceosomal small nuclear ribonucleoprotein (snRNP) complexes. SNRPD1 specifically interacts with Sm proteins (SNRPD2. SNRPD3. SNRPE, SNRPF, and SNRPG) to form the heptameric Sm ring, a conserved structure that binds to uridine-rich regions of spliceosomal snRNAs (e.g., U1. U2. U4. U5). This interaction is critical for snRNP biogenesis, nuclear localization, and spliceosome activation during splicing.
Recombinant SNRPD1 protein is produced in vitro using expression systems like *E. coli* or mammalian cells, often with affinity tags (e.g., His-tag) for purification. Its recombinant form enables structural studies (e.g., X-ray crystallography, cryo-EM) to dissect spliceosome assembly mechanisms and protein-RNA interactions. Researchers also utilize it to investigate dysregulated splicing in diseases, including cancers and neurodegenerative disorders. For instance, SNRPD1 overexpression correlates with tumor progression in several cancers, while its mutations or altered expression may contribute to spinal muscular atrophy (SMA) due to disrupted SMN (survival of motor neuron) complex function.
As a key splicing factor, SNRPD1 has emerging roles in therapeutic development. Its recombinant version aids in high-throughput screens for splicing-modulating drugs or in studying autoimmune responses linked to anti-Sm antibodies in lupus. Ongoing research focuses on elucidating its post-translational modifications, splice isoform diversity, and tissue-specific functions to advance precision medicine approaches.
×
